CavaGene harnesses genomic and AI technology to deliver early, personalized cancer diagnostics through non-invasive, saliva-based testing—bridging innovative research with practical healthcare solutions.

Pictured - David Hur

Points of Differentiation

Comprehensive Biomarker Detection: Uses advanced AI to detect a broad range of cancer markers with reduced false positives.
Rapid, Non-Invasive Testing: Saliva-based testing delivers results within 48 hours for accessible diagnostics.
Dynamic Risk Profiling: Continuously adjusts cancer risk probabilities by integrating genetic, environmental, and lifestyle factors.

Supplementary Images

Team Video

Team

David Hur, Stern E.M.B.A. ’26

Contact us

Days :
Hours :
Minutes :
Seconds


Take your startup further, faster
with NYU's Premier Venture Competition

NYU Entrepreneurs Challenge

APPLICATION CLOSING

DEADLINE: SUNDAY DECEMBER 1 @ 11:59 PM EST

Days :
Hours :
Minutes :
Seconds


See NYU's top startups
of Face off for $225K In Seed funding

NYU Entrepreneurs Challenge

Final Pitch Off & Awards

Friday, April 26th